Convergence Pharma

Babraham, United Kingdom Founded: 2010 • Age: 16 yrs Acquired By Biogen
Novel analgesics are developed for chronic pain via ion-channel modulation.
Request Access

About Convergence Pharma

Convergence Pharma is a company based in Babraham (United Kingdom) founded in 2010 was acquired by Biogen in January 2015.. Convergence Pharma has raised $35.4 million across 1 funding round from investors including Biogen, New Leaf Venture Partners and Apposite Capital. Convergence Pharma operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.

  • Headquarter Babraham, United Kingdom
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Old Convergence Pharmaceuticals Limited
  • Date of Incorporation 18 Jun, 2010
  • Jurisdiction MAIDENHEAD, BERKSHIRE, ENGLAND
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $35.4 M (USD)

    in 1 rounds

  • Latest Funding Round
    $35.4 M (USD), Series A

    Oct 04, 2010

  • Investors
    Biogen

    & 3 more

  • Employee Count
    Employee Count
  • Acquired by
    Biogen

    (Jan 11, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Convergence Pharma

Convergence Pharma has successfully raised a total of $35.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $35.4 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $35.4M
  • First Round

    (04 Oct 2010)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2010 Amount Series A - Convergence Pharma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Convergence Pharma

Convergence Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, New Leaf Venture Partners and Apposite Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Stage-agnostic investments in US life sciences are managed.
Founded Year Domain Location
Healthcare impact investments are managed by Apposite Capital.
Founded Year Domain Location
Venture capital fund focused on early-stage healthcare startups
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Convergence Pharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Convergence Pharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Convergence Pharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Convergence Pharma

Convergence Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of therapies for the treatment of musculoskeletal disorders
domain founded_year HQ Location
Develops antibody-based treatments for autoimmune and inflammatory disorders.
domain founded_year HQ Location
Drug delivery systems for CNS disorders and pain are developed.
domain founded_year HQ Location
Reformulated injectables for chemotherapy side effects and pain are developed.
domain founded_year HQ Location
Therapies for pain and addiction treatment are developed.
domain founded_year HQ Location
Therapeutics for pain management are developed with abuse-deterrent designs.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Convergence Pharma

Frequently Asked Questions about Convergence Pharma

When was Convergence Pharma founded?

Convergence Pharma was founded in 2010.

Where is Convergence Pharma located?

Convergence Pharma is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.

Is Convergence Pharma a funded company?

Convergence Pharma is a funded company, having raised a total of $35.4M across 1 funding round to date. The company's 1st funding round was a Series A of $35.4M, raised on Oct 04, 2010.

What does Convergence Pharma do?

Convergence Pharmaceuticals was formed in 2010 after neuroscience clinical assets were acquired from GlaxoSmithKline. Focus is placed on biotechnology for novel analgesics targeting chronic pain through ion-channel modulation, including a pipeline of clinical-stage compounds for voltage-gated sodium channels. Operations are conducted from Babraham, United Kingdom, in the analgesics sector. The company was acquired by Biogen in February 2015.

Who are the top competitors of Convergence Pharma?

Convergence Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.

Who are Convergence Pharma's investors?

Convergence Pharma has 4 investors. Key investors include Biogen, New Leaf Venture Partners, Apposite Capital, and SV Health Investors.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available